Raltegravir, sold under the brand name Isentress, is an antiretroviral medication used, together with other medication, to treat HIV/AIDS.[5] It may also be used, as part of post exposure prophylaxis, to prevent HIV infection following potential exposure.[6] It is taken by mouth.[5]
Common side effects include trouble sleeping, feeling tired, nausea, high blood sugar, and headaches.[6] Severe side effects may include allergic reactions including Stevens–Johnson syndrome, muscle breakdown, and liver problems.[6] It is unclear if use during pregnancy or breastfeeding is safe.[6] Raltegravir is an HIV integrase strand transfer inhibitor which blocks the functioning of HIV integrase which is needed for viral replication.[6]
Raltegravir was approved for medical use in the United States in 2007.[6] It is on the World Health Organization's List of Essential Medicines.[7] Lamivudine/raltegravir, a combination with lamivudine, is also available.[6]
^"Product monograph brand safety updates". Health Canada. 7 July 2016. Retrieved 1 April 2024.
^"Isentress 400 mg Film-coated Tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 11 July 2021.
^"Isentress- raltegravir tablet, film coated Isentress- raltegravir tablet, chewable Isentress- raltegravir granule, for suspension". DailyMed. Retrieved 11 July 2021.
^"Isentress EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 12 July 2021.
^ abBritish national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 429. ISBN 978-0-85711-156-2.
^ abcdefg"Raltegravir Potassium". The American Society of Health-System Pharmacists. Retrieved 8 December 2017.
^World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
Raltegravir, sold under the brand name Isentress, is an antiretroviral medication used, together with other medication, to treat HIV/AIDS. It may also...
for raltegravir (brand name Isentress). Research published at the time supported the conclusion that "[for people living with HIV,] raltegravir plus...
all known and appear in a variety of pharmaceutical drugs including raltegravir, butalamine, fasiplon, oxolamine, and pleconaril. The 1,2,3-isomer is...
3.54% Johnson & Johnson HIV infection Jun-2006 Mon-20XX 61 Isentress Raltegravir 248,924 0.72% Merck & Co., Inc. HIV Infection Dec-1998 Mon-20XX 62 Janumet...
of drugs used in the treatment of HIV. The first integrase inhibitor, raltegravir, was approved in 2007 and other drugs were in clinical trials in 2011...
integration, eventually leading to HIV integrase inhibitors such as raltegravir in 2008. Additionally, Montano et al. created a crystal structure of...
Laboratory, Chilton, Oxfordshire, England, UK; a national research lab Raltegravir, an antiretroviral medication Zearalenone, an estrogenic metabolite Ral...
Food and Drug Administration (U.S.) approved the integrase inhibitor Raltegravir (MK-0518, brand name Isentress). The second integrase inhibitor, elvitegravir...
into the host cell genome. Examples of integrase inhibitors include raltegravir, elvitegravir, and dolutegravir. Once a virus genome becomes operational...
peptide HIV entry inhibitor Nonbenzodiazepines like zolpidem and zopiclone Raltegravir, an HIV integrase inhibitor SSRIs (selective serotonin reuptake inhibitors)...
of the first HIV integrase inhibitor to gain FDA approval, Isentress (raltegravir). Her lab also determined these inhibitors' mechanism of action and ways...
Flexner, C.; Goh, B. C. (2011). "Simultaneous determination of raltegravir and raltegravir glucuronide in human plasma by liquid chromatography-tandem mass...
often used in women who are diagnosed with HIV late in their pregnancy. Raltegravir (RAL) is the most commonly used. Non-nucleoside reverse transcriptase...
Global Information
